Antibody adjuvant conjugates
US11110178B2 · kind B2 · utility
3Cited by
122References
30Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 13, 2020 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Mar 13, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.